Halozyme Therapeutics (HALO) : Zacks Investment Research ranks Halozyme Therapeutics (HALO) as 3, which is a Hold recommendation. 4 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. Not everyone is convinced about the stocks future, hence, the stock receives 1 Sell recommendation. The average broker rating of 5 research analysts is 1.6, which indicates as a Buy.
Halozyme Therapeutics (HALO) has been rated by 3 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $16 and the lowest price target forecast is $7. The average forecast of all the analysts is $12.58 and the expected standard deviation is $5.08.
For the current week, the company shares have a recommendation consensus of Buy.
Halozyme Therapeutics (NASDAQ:HALO): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $9.98 and $9.87 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $10.40. The buying momentum continued till the end and the stock did not give up its gains. It closed at $10.39, notching a gain of 3.59% for the day. The total traded volume was 1,031,989 . The stock had closed at $10.03 on the previous day.
Halozyme Therapeutics, Inc. is a biotechnology company, which is focused on developing and commercializing oncology therapies that target the tumor microenvironment. The Companys development pipeline consists primarily of clinical-stage product candidates in oncology and diabetes. The product candidates in its pipeline are based on rHuPH20, a human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA). Its lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a new molecular entity, under development for the systemic treatment of tumors that accumulate HA. The Company is in collaboration with pharmaceutical companies including, Roche, Pfizer, Janssen and Baxter for its drug delivery platform, ENHANZE, which enables biologics and small molecule compounds that are administered intravenously to be delivered subcutaneously.